MedTrace Logo

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-22

No results posted yet for this study

Summary

Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).

Conditions

Interventions

DEVICE

Nordlys SWT IPL

Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators

PROCEDURE

Meibomian Gland Expression (MGX)

Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction

DEVICE

Sham Nordlys SWT IPL

Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off

Sponsors & Collaborators

  • Candela Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-18
Primary Completion
2025-09-30
Completion
2025-09-30
FDA Device
Yes

Countries

  • United States
  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06064071 on ClinicalTrials.gov